Cargando…

494. Real-world effectiveness of tixagevimab/cilgavimab for COVID-19 pre-exposure prophylaxis in solid organ transplant recipients during the Omicron variant period

BACKGROUND: Pre-exposure prophylaxis (PrEP) with a combination of long-acting monoclonal antibodies with tixagevimab/cilgavimab (T/C) have provided viral neutralizing activity against SARS-CoV-2 and protected solid organ transplant recipients (SOTRs) that produced poor immunogenicity after COVID-19...

Descripción completa

Detalles Bibliográficos
Autores principales: Rojanakit, Gun, Kiertiburanakul, Sasisopin, Boongird, Sarinya, Sutharattanapong, Napan, Yingchoncharoen, Teerapat, Sobhonslidsuk, Abhasnee, Bruminhent, Jackrapong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10678462/
http://dx.doi.org/10.1093/ofid/ofad500.563
_version_ 1785150367429820416
author Rojanakit, Gun
Kiertiburanakul, Sasisopin
Boongird, Sarinya
Sutharattanapong, Napan
Yingchoncharoen, Teerapat
Sobhonslidsuk, Abhasnee
Bruminhent, Jackrapong
author_facet Rojanakit, Gun
Kiertiburanakul, Sasisopin
Boongird, Sarinya
Sutharattanapong, Napan
Yingchoncharoen, Teerapat
Sobhonslidsuk, Abhasnee
Bruminhent, Jackrapong
author_sort Rojanakit, Gun
collection PubMed
description BACKGROUND: Pre-exposure prophylaxis (PrEP) with a combination of long-acting monoclonal antibodies with tixagevimab/cilgavimab (T/C) have provided viral neutralizing activity against SARS-CoV-2 and protected solid organ transplant recipients (SOTRs) that produced poor immunogenicity after COVID-19 immunization. However, real-world data on the effectiveness and safety of T/C in SOTRs during the Omicron wave is limited. METHODS: A prospective study at a single transplant center was conducted to evaluate the effectiveness and adverse events (AE) of T/C among SOTRs during the BA.2.75 Omicron lineages period (August 2022 to February 2023). T/C of 150/150 and 300/300 mg doses were provided from August 2022 to December 2022 and after, respectively. RESULTS: A total of 39 SOTRs comprising kidney (n= 29), liver (n=2), and heart (n=8) transplant recipients were included in the study. Thirty-three (85%) and 6 (15%) SOTRs received 150/150 and 300/300 mg of T/C, respectively. The median (IQR) age was 52 (35-62) years. Twenty-two (56%) had a prior history of COVID-19. The median (IQR) number of COVID-19 vaccine was 4 (3-4) doses. During the median follow-up of 6.35 (5-8.33) months, COVID-19 developed in 5 (12.8%) out of 39 SOTRs with a median (IQR) time of 73 (36-115) days from receiving T/C. None of those who received a 300/300 mg dose developed COVID-19. There was no severe COVID-19 or death observed. Five (12.8%) SOTRs reported mild and reversible AEs with pain at injection (n=2), fever (n=3), and muscle aches (n=1). There was no allograft rejection reported. CONCLUSION: Breakthrough SARS-CoV-2 infection remains among fully vaccinated SOTRs receiving T/C as PrEP and subjects to concurrent circulating strain in the community. However, the disease severity appears mild, and the short-term safety profile seems tolerable. DISCLOSURES: All Authors: No reported disclosures
format Online
Article
Text
id pubmed-10678462
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Oxford University Press
record_format MEDLINE/PubMed
spelling pubmed-106784622023-11-27 494. Real-world effectiveness of tixagevimab/cilgavimab for COVID-19 pre-exposure prophylaxis in solid organ transplant recipients during the Omicron variant period Rojanakit, Gun Kiertiburanakul, Sasisopin Boongird, Sarinya Sutharattanapong, Napan Yingchoncharoen, Teerapat Sobhonslidsuk, Abhasnee Bruminhent, Jackrapong Open Forum Infect Dis Abstract BACKGROUND: Pre-exposure prophylaxis (PrEP) with a combination of long-acting monoclonal antibodies with tixagevimab/cilgavimab (T/C) have provided viral neutralizing activity against SARS-CoV-2 and protected solid organ transplant recipients (SOTRs) that produced poor immunogenicity after COVID-19 immunization. However, real-world data on the effectiveness and safety of T/C in SOTRs during the Omicron wave is limited. METHODS: A prospective study at a single transplant center was conducted to evaluate the effectiveness and adverse events (AE) of T/C among SOTRs during the BA.2.75 Omicron lineages period (August 2022 to February 2023). T/C of 150/150 and 300/300 mg doses were provided from August 2022 to December 2022 and after, respectively. RESULTS: A total of 39 SOTRs comprising kidney (n= 29), liver (n=2), and heart (n=8) transplant recipients were included in the study. Thirty-three (85%) and 6 (15%) SOTRs received 150/150 and 300/300 mg of T/C, respectively. The median (IQR) age was 52 (35-62) years. Twenty-two (56%) had a prior history of COVID-19. The median (IQR) number of COVID-19 vaccine was 4 (3-4) doses. During the median follow-up of 6.35 (5-8.33) months, COVID-19 developed in 5 (12.8%) out of 39 SOTRs with a median (IQR) time of 73 (36-115) days from receiving T/C. None of those who received a 300/300 mg dose developed COVID-19. There was no severe COVID-19 or death observed. Five (12.8%) SOTRs reported mild and reversible AEs with pain at injection (n=2), fever (n=3), and muscle aches (n=1). There was no allograft rejection reported. CONCLUSION: Breakthrough SARS-CoV-2 infection remains among fully vaccinated SOTRs receiving T/C as PrEP and subjects to concurrent circulating strain in the community. However, the disease severity appears mild, and the short-term safety profile seems tolerable. DISCLOSURES: All Authors: No reported disclosures Oxford University Press 2023-11-27 /pmc/articles/PMC10678462/ http://dx.doi.org/10.1093/ofid/ofad500.563 Text en © The Author(s) 2023. Published by Oxford University Press on behalf of Infectious Diseases Society of America. https://creativecommons.org/licenses/by/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/), which permits unrestricted reuse, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Abstract
Rojanakit, Gun
Kiertiburanakul, Sasisopin
Boongird, Sarinya
Sutharattanapong, Napan
Yingchoncharoen, Teerapat
Sobhonslidsuk, Abhasnee
Bruminhent, Jackrapong
494. Real-world effectiveness of tixagevimab/cilgavimab for COVID-19 pre-exposure prophylaxis in solid organ transplant recipients during the Omicron variant period
title 494. Real-world effectiveness of tixagevimab/cilgavimab for COVID-19 pre-exposure prophylaxis in solid organ transplant recipients during the Omicron variant period
title_full 494. Real-world effectiveness of tixagevimab/cilgavimab for COVID-19 pre-exposure prophylaxis in solid organ transplant recipients during the Omicron variant period
title_fullStr 494. Real-world effectiveness of tixagevimab/cilgavimab for COVID-19 pre-exposure prophylaxis in solid organ transplant recipients during the Omicron variant period
title_full_unstemmed 494. Real-world effectiveness of tixagevimab/cilgavimab for COVID-19 pre-exposure prophylaxis in solid organ transplant recipients during the Omicron variant period
title_short 494. Real-world effectiveness of tixagevimab/cilgavimab for COVID-19 pre-exposure prophylaxis in solid organ transplant recipients during the Omicron variant period
title_sort 494. real-world effectiveness of tixagevimab/cilgavimab for covid-19 pre-exposure prophylaxis in solid organ transplant recipients during the omicron variant period
topic Abstract
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10678462/
http://dx.doi.org/10.1093/ofid/ofad500.563
work_keys_str_mv AT rojanakitgun 494realworldeffectivenessoftixagevimabcilgavimabforcovid19preexposureprophylaxisinsolidorgantransplantrecipientsduringtheomicronvariantperiod
AT kiertiburanakulsasisopin 494realworldeffectivenessoftixagevimabcilgavimabforcovid19preexposureprophylaxisinsolidorgantransplantrecipientsduringtheomicronvariantperiod
AT boongirdsarinya 494realworldeffectivenessoftixagevimabcilgavimabforcovid19preexposureprophylaxisinsolidorgantransplantrecipientsduringtheomicronvariantperiod
AT sutharattanapongnapan 494realworldeffectivenessoftixagevimabcilgavimabforcovid19preexposureprophylaxisinsolidorgantransplantrecipientsduringtheomicronvariantperiod
AT yingchoncharoenteerapat 494realworldeffectivenessoftixagevimabcilgavimabforcovid19preexposureprophylaxisinsolidorgantransplantrecipientsduringtheomicronvariantperiod
AT sobhonslidsukabhasnee 494realworldeffectivenessoftixagevimabcilgavimabforcovid19preexposureprophylaxisinsolidorgantransplantrecipientsduringtheomicronvariantperiod
AT bruminhentjackrapong 494realworldeffectivenessoftixagevimabcilgavimabforcovid19preexposureprophylaxisinsolidorgantransplantrecipientsduringtheomicronvariantperiod